Treatment of anemia with darbepoetin alfa in systolic heart failure

New England Journal of Medicine

Volumn 368, Issue 13, 2013, Pages 1210-1219

  Swedberg, Karl ^a   Young, James B ^b   Anand, Inder S ^c   Cheng, Sunfa ^d   Desai, Akshay S ^e   Diaz, Rafael ^f   Maggioni, Aldo P ^g   McMurray, John J V ^h   O'Connor, Christopher ⁱ   Pfeffer, Marc A ^e   Solomon, Scott D ^e   Sun, Yan ^d   Tendera, Michal ^j   Van Veldhuisen, Dirk J ^k  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d AMGEN INC   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f Estudios Clínicos Latino América and Instituto Cardiovascular de Rosario   (Argentina)

^g Italian Association of Hospital Cardiologists Research Center   (Italy)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

^j MEDICAL UNIVERSITY OF SILESIA   (Poland)

^k UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN; IRON; MINERALOCORTICOID ANTAGONIST; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; TRANSFERRIN;

ADULT; AGED; ANEMIA; ARTERIAL THROMBOEMBOLISM; ARTERY EMBOLISM; ARTICLE; BRAIN HEMORRHAGE; CARDIAC RESYNCHRONIZATION THERAPY; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CONVULSION; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG WITHDRAWAL; EMBOLISM; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; HYPERTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IRON BLOOD LEVEL; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; SYSTOLIC HEART FAILURE; THROMBOEMBOLISM; TRANSFERRIN BLOOD LEVEL; TREATMENT RESPONSE; VASCULAR ACCESS; VEIN EMBOLISM; VENOUS THROMBOEMBOLISM;

EID: 84875500204     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1214865     Document Type: Article

References (23)

1. O'Meara E, Murphy C, McMurray JJ. Anemia and heart failure. Curr Heart Fail Rep 2004;1:176-82.
2. Anand I, McMurray JJ, Whitmore J, et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 2004;110:149-54. (Pubitemid 38924582)
3. Maggioni AP, Opasich C, Anand I, et al. Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. J Card Fail 2005;11:91-8. (Pubitemid 40269782)
4. O'Meara E, Clayton T, McEntegart MB, et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 2006;113:986-94. (Pubitemid 43879474)
5. Komajda M, Anker SD, Charlesworth A, et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 2006;27:1440-6. (Pubitemid 43998078)
6. Anand IS. Pathophysiology of anemia in heart failure. Heart Fail Clin 2010;6:279-88.
7. Westenbrink BD, Voors AA, de Boer RA, et al. Bone marrow dysfunction in chronic heart failure patients. Eur J Heart Fail 2010;12:676-84.
8. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001;37:1775-80. (Pubitemid 32499958)
9. Cleland JG, Sullivan JT, Ball S, et al. Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation. J Cardiovasc Pharmacol 2005;46:155-61. (Pubitemid 41060207)
10. Ngo K, Kotecha D, Walters JA, et al. Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev 2010;1:CD007613.
11. Ghali JK, Anand IS, Abraham WT, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008;117:526-35.
12. Ponikowski P, Anker SD, Szachniewicz J, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2007;49:753-62. (Pubitemid 46240705)
13. van Veldhuisen DJ, Dickstein K, Cohen-Solal A, et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007;28:2208-16. (Pubitemid 47428946)
14. Klapholz M, Abraham WT, Ghali JK, et al. The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. Eur J Heart Fail 2009;11:1071-7.
15. van der Meer P, Groenveld HF, Januzzi JL Jr, van Veldhuisen DJ. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 2009;95:1309-14.
16. Pfeffer MA, Burdmann EA, Chen C-Y, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32.
17. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-98. (Pubitemid 44749317)
18. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90. (Pubitemid 28385655)
19. McMurray JJ, Anand IS, Diaz R, et al. Design of the Reduction of Events with Darbepoetin Alfa in Heart Failure (REDHF): a phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 2009;11:795-801. [Erratum, Eur J Heart Fail 2010;12:765.]
20. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000;35:1245-55. (Pubitemid 30206900)
21. Pettersen KI, Reikvam A, Rollag A, Stavem K. Reliability and validity of the Kansas City cardiomyopathy questionnaire in patients with previous myocardial infarction. Eur J Heart Fail 2005;7:235-42. (Pubitemid 40215619)
22. McMurray JJV, Anand IA, Diaz R, et al. Baseline characteristics of patients in the Reduction of Events with Darbepoetin Alfa in Heart Failure trial (RED-HF). Eur J Heart Fail 2013;15:334-41.
23. Anand IS, Kuskowski MA, Rector TS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 2005;112:1121-7. (Pubitemid 41216118)